GLP-1R

CAT # Sunan samfur Bayani
Saukewa: CPD100594 TT15 TT15 agonist ne na GLP-1R.
Saukewa: CPD100593 Farashin 0453379 VU0453379 shine CNS-mai shiga glucagon-kamar peptide 1 mai karɓa (GLP-1R) tabbataccen allosteric modulator (PAM)
Saukewa: CPD100592 Saukewa: PF-06882961 PF-06882961 mai ƙarfi ne mai ƙarfi, mai haɓakawa na baka na mai karɓar glucagon-kamar peptide-1 (GLP-1R).
Saukewa: CPD100591 Saukewa: PF-0637222 PF-06372222 ƙananan ƙwayoyin cuta mara kyau na allosteric modulator (NAM) na mai karɓar glucagon (GCGR). Masu adawa da GCGR na iya taimakawa wajen magance nau'in ciwon sukari na 2 saboda suna daidaita matakan glucose na plasma ta hanyar raguwa ko rage yawan samar da glucose na hanta ta hanyar sigina a cikin hanta, tsoka mai santsi na hanji, koda, kwakwalwa, da adipose tissue. PF-06372222 kuma mai adawa ne ga mai karɓar glucagon-kamar peptide-1 GLP-1R, wanda ke hana ƙwayar glucagon da siginar insulin-dogara kuma yana iya taka rawa a cikin sakin hormonal wanda ke haifar da matsananciyar damuwa da damuwa. Ta hanyar canza GLP-1R mara kyau, PF-06372222 na iya magance nau'in ciwon sukari na 2 da damuwa da damuwa.
Saukewa: CPD100590 NNC0640 NNC0640 shine mummunan allosteric modulator na glucagon-kamar peptide-1 mai karɓa (GLP-1R).
Saukewa: CPD100589 Saukewa: HTL26119 HTL26119 sabon allosteric antagonist na mai karɓar glucagon-kamar peptide-1 (GLP-1R).
da

Tuntube Mu

Tambaya

Sabbin Labarai

  • Manyan Abubuwa 7 A cikin Binciken Magunguna A cikin 2018

    Manyan Abubuwa 7 A Cikin Binciken Magunguna Na...

    Kasancewar kasancewa ƙarƙashin matsin lamba don yin gasa a cikin yanayi mai ƙalubale na tattalin arziki da fasaha, dole ne kamfanonin harhada magunguna da fasahar kere-kere su ci gaba da haɓaka cikin shirye-shiryensu na R&D don ci gaba ...

  • ARS-1620: Sabuwar mai hanawa don KRAS-mutant cancers

    ARS-1620: Sabuwar mai hanawa don K ...

    A cewar wani binciken da aka buga a cikin Cell, masu bincike sun kirkiro wani takamaiman mai hanawa don KRASG12C mai suna ARS-1602 wanda ya haifar da koma baya a cikin mice. "Wannan binciken yana ba da shaida a cikin vivo shaida cewa mutant KRAS na iya zama ...

  • AstraZeneca yana karɓar haɓakar tsari don magungunan oncology

    AstraZeneca yana karɓar haɓaka tsari don ...

    AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna. ...

WhatsApp Online Chat!